Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» UCB Pharma
UCB Pharma
UCB posts more supportive data from Humira rival bimekizumab
Pharmaforum
Fri, 12/6/19 - 09:31 pm
UCB Pharma
bimekizumab
AbbVie
Humira
psoriasis
biosimilars
UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA
Endpoints
Fri, 11/15/19 - 11:12 am
UCB Pharma
bimekizumab
psoriasis
clinical trials
UCB's bispecific beats J&J's Stelara in psoriasis phase 3
Fierce Biotech
Fri, 10/18/19 - 07:47 pm
UCB Pharma
bispecific antibodies
bimekizumab
JNJ
Stelara
psoriasis
UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy
Endpoints
Thu, 10/17/19 - 10:24 am
UCB Pharma
Amgen
psoriasis
bimekizumab
UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris
Fierce Biotech
Thu, 10/10/19 - 12:56 pm
UCB Pharma
Ra Pharmaceuticals
M&A
zilucoplan
Alexion
Soliris
Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug
Endpoints
Fri, 06/28/19 - 10:04 am
Amgen
UCB Pharma
FDA
EMA
Europe
osteoporosis
Evenity
romosozumab
FDA approves Evenity for osteoporosis
BioCentury
Tue, 04/9/19 - 07:03 pm
FDA
Evenity
romosozumab
Amgen
UCB Pharma
osteoporosis
UCB Debuts AI Powered Virtual Assistant Parkinson's Disease App
CP WIre
Thu, 11/15/18 - 10:49 am
UCB Pharma
Parkinson's Disease
artificial intelligence
mobile apps
UCB Debuts AI Powered Virtual Assistant Parkinson's Disease App
Thu, 11/15/18 - 09:18 am
UCB Pharma
Parkinson's Disease
AI
Biogen sees two phase 2 failures: In sciatica and in its lupus collaboration with UCB
Fierce Biogen
Tue, 10/23/18 - 01:40 pm
UCB Pharma
Biogen
dapirolizumab pegol
vixotrigine
lupus
sciatica
UCB, Biogen admit defeat in PhII lupus trial, adding to a string of late-stage failures in the field
Endpoints
Tue, 10/23/18 - 10:37 am
UCB Pharma
Biogen
dapirolizumab pegol
DZP
lupus
clinical trials
Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead
Endpoints
Fri, 07/13/18 - 11:57 am
Amgen
UCB Pharma
osteoporosis
romosozumab
US approves UCB’s Cimzia for psoriasis
Pharma Times
Tue, 05/29/18 - 09:16 pm
FDA
UCB Pharma
Cimzia
psoriasis
Briviact (Brivaracetam) Wins Approval to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients
CP Wire
Mon, 05/14/18 - 09:40 am
UCB Pharma
FDA
Briviact
partial onset seizures
epilepsy
pediatric epilepsy
UCB Receives Positive CHMP Opinion for Cimzia in Moderate-to-Severe Plaque Psoriasis
CP Wire
Sat, 04/28/18 - 11:56 am
UCB Pharma
CHMP
Cimzia
psoriasis
AbbVie, Allergan, Roche could join Biogen, UCB in Acorda hunt: analyst
Fierce Pharma
Fri, 02/16/18 - 09:38 pm
AbbVie
Allergan
Roche
Biogen
UCB Pharma
Acorda Therapeutics
M&A
Biogen, UCB step up to kick the tires at Acorda as buyout buzz grows — report
Endpoints
Fri, 01/19/18 - 11:15 am
Biogen
UCB Pharma
Acorda Therapeutics
M&A
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why
Yahoo/Zacks.com
Sat, 11/25/17 - 12:29 pm
Nektar
AstraZeneca
Movantik
Onzeald
UCB Pharma
Cimzia
Amgen
Neulasta
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
Yahoo/Zacks.com
Sat, 09/2/17 - 11:11 am
Parkinson's Disease
Novartis
Teva Pharmaceutial
UCB Pharma
MEDI1341
AstraZeneca
Takeda
PRX002
Prothena
Roche
Acorda
Inbrija
Adamas Pharmaceuticals
Gocovri
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
Endpoints
Mon, 07/17/17 - 09:15 am
FDA
Amgen
osteoporosis
romosozumab
UCB Pharma
Radius Health
Tymlos
Pages
« first
‹ previous
1
2
3
4
next ›
last »